Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

• DOI: 10.1136/bjo.2007.123513
• Publication Date: 2008-01-23T01:24:46Z
• Authors: T. C. Kreutzer; C. S. Alge; A. H. Wolf; D. Kook; J. Burger; R. Strauss; C. Kunze; C. Haritoglou; A. Kampik; S. Priglinger
• Keywords: Adult; Aged, 80 and over; Male; Vascular Endothelial Growth Factor A; Fovea Centralis; Visual Acuity; Antibodies, Monoclonal; Angiogenesis Inhibitors; Middle Aged; Antibodies, Monoclonal, Humanized; Drug Administration Schedule; Macular Edema; Injections; 3. Good health; Bevacizumab; Vitreous Body; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Retinal Vein Occlusion; Humans; Female; Aged

To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.Patients presented at a mean age of 69 years (range 44-86). Mean duration of symptoms was 40 weeks (range 1-300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) microm, declining to 316 (41) microm at 6 months.Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.